BLASTOHIT2012

Clarifying the role of Blastocystis in human intestinal disease

Coordinatore	TEAGASC - AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY    more  Organization address address: Oak Park city: CARLOW contact info Titolo: Dr. Nome: Paul Cognome: Cotter Email: send email Telefono: +353 25 42694 Fax: +353 25 42694
Nazionalità Coordinatore	Ireland [IE]
Totale costo	246˙782 €
EC contributo	246˙782 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IEF
Funding Scheme	MC-IEF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-13   -   2015-09-12

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	TEAGASC - AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY  Organization address address: Oak Park city: CARLOW contact info Titolo: Dr. Nome: Paul Cognome: Cotter Email: send email Telefono: +353 25 42694 Fax: +353 25 42694	IE (CARLOW)	coordinator	246˙782.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'It is now realised that the human intestinal microbiota is central to health and wellbeing. However, the vast amount of research into the human microbiome has focused primarily on the prokaryotic (bacterial) component of this complex microbial ecosystem and we understand virtually nothing of the eukaryotic species, such as the protists, that are known to play critical roles in structuring microbial communities in other natural ecosystems. Blastocystis is the most common protist in the human intestinal tract (IT); current estimates indicate that it colonises up to 1 billion people worldwide. Crucially, Blastocystis is considered to be an emerging pathogen, but its role in human illness and disease is both controversial and unclear. The key research goal of this project is to clarify the role of Blastocystis in human intestinal health and disease. For this project there will be a specific focus on Irritable Bowel Syndrome (IBS). We will analyse the prevalence and genetic diversity of Blastocystis in IBS together with healthy individuals and study the interactions between Blastocystis and specific intestinal bacteria. We will use an integrated series of state-of-the-art experiments encompassing both quantitative and qualitative analysis. These include a novel high-throughput PCR with high genetic resolution to assess Blastocystis variation in IBS and healthy groups, next-generation sequence analysis of IT bacteria, quantitative PCR, virulence assays, in vitro microcosm experiments and phenotypic assays. The novel interdisciplinary framework outlined in this proposal that combines molecular microbial surveys of the human IT with experimental microbial ecology and evolution, will allow us to address unresolved and original research questions. Data from this study also has the potential for commercialisation including the development of novel therapeutic treatments.'